Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

PHASE3CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

May 1, 2020

Study Completion Date

May 1, 2020

Conditions
Hypogonadism, Male
Interventions
DRUG

SOV2012-F1

Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU

Trial Locations (19)

10016

Manhattan Medical Research Practice, PLLC, New York

11530

Accumed Research Associates, Garden City

19004

Urologic Consultant of SE Pennyslvania, Bala-Cynwyd

28314

Rapha Institute for Clinical Research, Fayetteville

29464

Coastal Carolina Research Center, Mt. Pleasant

32223

Jacksonville Impotence Treatment Center, Jacksonville

32765

Oviedo Medical Research, LLC, Oviedo

33155

My Community Research Center, Miami

33180

South Florida Medical Research, Aventura

33511

PAB Clinical Research, Brandon

33709

Meridien Research, St. Petersburg

35235

Alabama Clinical Therapeutics, LLC, Birmingham

36608

Coastal Clinic Research Inc, Mobile

37411

University Diabetes Endocrine Consultants, Chattanooga

68114

Quality Clinical Research, Inc., Omaha

70601

Centex Studies, Inc., Lake Charles

77058

Centex Studies, Inc., Houston

83704

Northwest Clinical Trials, Boise

89148

Palm Research Center, Inc., Las Vegas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Marius Pharmaceuticals

INDUSTRY